Merck (NYSE:MRK) was one of the earliest investors in Moderna (NASDAQ:MRNA), buying a position in the biotech even before it went public in late 2018. Earlier this month, though, Merck announced that it had sold all of its shares of Moderna, making a sizable profit. In this Motley Fool Live video recorded on Dec. 9, 2020, Healthcare and Cannabis Bureau Chief Corinne Cardina and Fool.com writer Keith Speights discuss why it appears that Merck made a mistake by selling its Moderna stake.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,